Vertex Pharmaceuticals, Inc [VRTX] stock prices are up 1.45% to $495.42 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The VRTX shares have gain 0.77% over the last week, with a monthly amount glided 5.42%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] stock has seen the most recent analyst activity on February 12, 2025, when Canaccord Genuity upgraded its rating to a Hold and also boosted its price target to $424 from $408. Previously, Canaccord Genuity upgraded its rating to Hold on February 11, 2025. On January 30, 2025, downgrade downgraded it’s rating to Equal Weight but maintained its price target of $460 on the stock. H.C. Wainwright reiterated its Buy rating and decreased its price target to $535 on December 20, 2024. Oppenheimer downgraded its rating to a Perform. Jefferies upgraded its rating to Buy for this stock on December 09, 2024, and upped its price target to $550. In a note dated November 14, 2024, Citigroup initiated an Buy rating and provided a target price of $575 on this stock.
The stock price of Vertex Pharmaceuticals, Inc [VRTX] has been fluctuating between $377.85 and $519.88 over the past year. Currently, Wall Street analysts expect the stock to reach $494.56 within the next 12 months. Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] shares were valued at $495.42 at the most recent close of the market. An investor can expect a potential drop of -0.17% based on the average VRTX price forecast.
Analyzing the VRTX fundamentals
The Vertex Pharmaceuticals, Inc [NASDAQ:VRTX] reported sales of 10.98B for trailing twelve months, representing a surge of 14.56%. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -0.02%, Pretax Profit Margin comes in at 0.02%, and Net Profit Margin reading is -0.05%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.03 and Total Capital is -0.01. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 486.79 points at the first support level, and at 478.17 for the second support level. However, for the 1st resistance point, the stock is sitting at 500.34, and for the 2nd resistance point, it is at 505.27.
Ratios To Look Out For
It’s worth pointing out that Vertex Pharmaceuticals, Inc [NASDAQ:VRTX]’s Current Ratio is 2.69. On the other hand, the Quick Ratio is 2.35, and the Cash Ratio is 1.28. Considering the valuation of this stock, the price to sales ratio is 11.58, the price to book ratio is 7.76.
Transactions by insiders
Recent insider trading involved WAGNER CHARLES F JR, EVP & Chief Financial Officer, that happened on Mar 10 ’25 when 3298.0 shares were sold. EVP, Chief Reg. & Quality Off., Tatsis Ourania completed a deal on Mar 10 ’25 to sell 3242.0 shares. Meanwhile, EVP, Chief Scientific Officer ALTSHULER DAVID sold 3231.0 shares on Mar 10 ’25.
